(Octreotide (Hospira), Sandostatin™)
Class: growth hormone inhibitor
Indication: acromegaly, gastro-entero pancreatic endocrine tumours, post pancreatic surgery, emergency treatment to stop bleeding oesophageal varices
Unlicensed indications: antisecretory in intestinal obstruction, secretory diarrhoea, high fistula output, variceal bleeds
Metabolism/clearance: metabolised by the liver
Syringe driver: see syringe driver compatibility table.
Mechanism of Action: blocks somatostatin receptors
Peak effect: 30 minutes
Duration: 12 hours
Full funding on Special Authority.
Cost: Approx $5.13 to $35.00 per normal release inj, $1,772 to $2,951 per LAR inj
Topic Code: 19446